Published 4 years ago • loading... • Updated 4 years ago
Illumina Wins Case Against FTC on Grail Acquisition
Summary by Ground News
The Federal Trade Commission has rejected a bid by Illumina to buy the early cancer detection company Grail. The San Diego-based company acquired Grail for $8 billion last year. Grail detects DNA sequence changes, chemical modifications, or other changes through a simple blood draw. The technology can detect a wide range of cancer types.